



Recombinant Binding Proteins and Genetically Engineered T-cells Targeting Intracellular Neoantigens

Guest Editors:

Prof. Dr. Thomas Böldicke

Helmholtz-Centre for Infection Research, Structure and Function of Proteins, Inhoffenstraße 7, D 38124 Braunschweig, Germany

Dr. Ana Maria Waaga-Gasser

1. Division of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
2. Department of Medicine, Harvard Medical School, Boston, MA 02115, USA

Deadline for manuscript submissions:

closed (25 February 2026)

Message from the Guest Editors

Dear Colleagues,

Two different strategies are currently at the forefront of clinical interest for targeting intracellular neoantigens in benign and malignant diseases: T-cell-receptor (TCR)-engineered T-cells and recombinant antibodies. Recombinant T-cell-based therapies targeting neoantigens use T-cells expressing a recombinant complete TCR (TCR-T-cell), a chimeric antigen receptor with the variable domains of a neopeptide-reactive TCR are fused to the chimeric antigen receptor as a binding domain (TCR-CAR T-cell) or a TCR-like antibody as a binding domain (TCR-like-CAR T-cell). In contrast to the use of recombinant T-cells, recombinant binding proteins, including antibodies, can be directly applied to cancer patients. The recombinant binding proteins targeting MHC/neopeptide complexes include DARPins, TCR-like antibodies, bispecific antibodies in the format CD3 x TCR-like antibody or CD3 x soluble TCR, as well as intrabodies. Both strategies have their pros and cons and will be discussed in this Special Issue.

Prof. Dr. Thomas Böldicke
Dr. Ana Maria Waaga-Gasser
Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Arne Skerra

Institute of Biological Chemistry,
Technical University Munich,
Emil-Erlenmeyer-Forum 5, 85350
Freising-Weihenstephan,
Germany

Message from the Editor-in-Chief

Antibodies is a relatively new journal with a major focus on quick dissemination of knowledge related to antibodies, especially how to quickly translate basic research results to therapeutic applications. Because it covers all areas related to antibodies unexpected connections between different areas could be made, leading to major discoveries and opening new fields of research and development. This is enhanced by the large readership of the many antibody-related areas of research. A specific priority area is human monoclonal antibodies for therapy of diseases and aging.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: CiteScore - Q2 (Drug Discovery)

Contact Us

Antibodies Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibodies
antibodies@mdpi.com
X@Antibodies_MDPI